{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:53:22Z","timestamp":1786402402486,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systematic quantification of phosphoprotein within cell signaling networks in solid tissues remains challenging and precise quantification in large scale samples has great potential for biomarker identification and validation. We developed a reverse phase protein array (RPPA) based phosphor-antibody characterization approach by taking advantage of the lysis buffer compatible with alkaline phosphatase (AP) treatment that differs from the conventional RPPA antibody validation procedure and applied it onto fresh frozen (FF) and formalin-fixed and paraffin-embedded tissue (FFPE) to test its applicability. By screening 106 phospho-antibodies using RPPA, we demonstrated that AP treatment could serve as an independent factor to be adopted for rapid phospho-antibody selection. We also showed desirable reproducibility and specificity in clincical specimens indicating its potential for tissue-based phospho-protein profiling. Of further clinical significance, using the same approach, based on melanoma and lung cancer FFPE samples, we showed great interexperimental reproducibility and significant correlation with pathological markers in both tissues generating meaningful data that match clinical features. Our findings set a benchmark of an efficient workflow for phospho-antibody characterization that is compatible with high-plex clinical proteomics in precison oncology.<\/jats:p>","DOI":"10.1038\/s41598-022-26715-9","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T12:03:16Z","timestamp":1672056196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A reverse phase protein array based phospho-antibody characterization approach and its applicability for clinical derived tissue specimens"],"prefix":"10.1038","volume":"12","author":[{"given":"Nan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Treumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"issue":"7","key":"26715_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/14789450.2017.1344101","volume":"14","author":"M Masuda","year":"2017","unstructured":"Masuda, M. & Yamada, T. Signaling pathway profiling using reverse-phase protein array and its clinical applications. Exp. Rev. Proteom. 14(7), 607\u2013615 (2017).","journal-title":"Exp. Rev. Proteom."},{"issue":"22","key":"26715_CR2","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1002\/pmic.200700484","volume":"7","author":"M Winters","year":"2007","unstructured":"Winters, M., Dabir, B., Yu, M. & Kohn, E. C. Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics 7(22), 4066\u20134068 (2007).","journal-title":"Proteomics"},{"issue":"4","key":"26715_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12014-010-9055-y","volume":"6","author":"BT Hennessy","year":"2010","unstructured":"Hennessy, B. T. et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin. Proteom. 6(4), 129\u2013151 (2010).","journal-title":"Clin. Proteom."},{"issue":"12","key":"26715_CR4","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1002\/pmic.200700676","volume":"8","author":"KL Ambroz","year":"2008","unstructured":"Ambroz, K. L., Zhang, Y., Schutz-Geschwender, A. & Olive, D. M. Blocking and detection chemistries affect antibody performance on reverse phase protein arrays. Proteomics 8(12), 2379\u20132383 (2008).","journal-title":"Proteomics"},{"issue":"10","key":"26715_CR5","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes, R. et al. Reverse phase protein array: Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5(10), 2512\u20132521 (2006).","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"26715_CR6","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/nprot.2008.179","volume":"3","author":"B Spurrier","year":"2008","unstructured":"Spurrier, B., Ramalingam, S. & Nishizuka, S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat. Protoc. 3(11), 1796\u20131808 (2008).","journal-title":"Nat. Protoc."},{"issue":"1","key":"26715_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13550-014-0034-6","volume":"4","author":"T Tegnebratt","year":"2014","unstructured":"Tegnebratt, T. et al. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. EJNMMI Res. 4(1), 34 (2014).","journal-title":"EJNMMI Res."},{"issue":"7","key":"26715_CR8","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1074\/mcp.O113.034918","volume":"13","author":"R Akbani","year":"2014","unstructured":"Akbani, R. et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: A workshop report: The RPPA (Reverse Phase Protein Array) society. Mol. Cell Proteom. 13(7), 1625\u20131643 (2014).","journal-title":"Mol. Cell Proteom."},{"issue":"4","key":"26715_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/prca.200800070","volume":"3","author":"J van Oostrum","year":"2009","unstructured":"van Oostrum, J. et al. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteom. Clin. Appl. 3(4), 412\u2013422 (2009).","journal-title":"Proteom. Clin. Appl."},{"key":"26715_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-61779-286-1_3","volume":"785","author":"V Espina","year":"2011","unstructured":"Espina, V., Mueller, C. & Liotta, L. A. Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology. Methods Mol. Biol. 785, 23\u201343 (2011).","journal-title":"Methods Mol. Biol."},{"issue":"26","key":"26715_CR11","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1038\/onc.2013.301","volume":"33","author":"H Guo","year":"2014","unstructured":"Guo, H. et al. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene 33(26), 3463\u20133472 (2014).","journal-title":"Oncogene"},{"issue":"4","key":"26715_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1074\/mcp.T500003-MCP200","volume":"4","author":"KM Sheehan","year":"2005","unstructured":"Sheehan, K. M. et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell Proteom. 4(4), 346\u2013355 (2005).","journal-title":"Mol. Cell Proteom."},{"issue":"1","key":"26715_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2009.10.016","volume":"46","author":"D Berg","year":"2010","unstructured":"Berg, D., Hipp, S., Malinowsky, K., Bollner, C. & Becker, K. F. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur. J. Cancer 46(1), 47\u201355 (2010).","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"26715_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040285","volume":"7","author":"K Malinowsky","year":"2012","unstructured":"Malinowsky, K. et al. Common protein biomarkers assessed by reverse phase protein arrays show considerable intratumoral heterogeneity in breast cancer tissues. PLoS ONE 7(7), e40285 (2012).","journal-title":"PLoS ONE"},{"issue":"1","key":"26715_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/jcp.22718","volume":"227","author":"D Berg","year":"2012","unstructured":"Berg, D. et al. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR. J. Cell Physiol. 227(1), 204\u2013212 (2012).","journal-title":"J. Cell Physiol."},{"issue":"1","key":"26715_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10549-015-3654-2","volume":"155","author":"OH Negm","year":"2016","unstructured":"Negm, O. H. et al. Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Res. Treat. 155(1), 25\u201335 (2016).","journal-title":"Breast Cancer Res. Treat."},{"issue":"23","key":"26715_CR17","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1158\/1078-0432.CCR-12-0452","volume":"18","author":"JD Wulfkuhle","year":"2012","unstructured":"Wulfkuhle, J. D. et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res. 18(23), 6426\u20136435 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"26715_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/path.2107","volume":"211","author":"KF Becker","year":"2007","unstructured":"Becker, K. F. et al. Quantitative protein analysis from formalin-fixed tissues: Implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 211(3), 370\u2013378 (2007).","journal-title":"J. Pathol."},{"issue":"4","key":"26715_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/PAI.0b013e3182054f9f","volume":"19","author":"D Berg","year":"2011","unstructured":"Berg, D. et al. Protein microarray-based comparison of HER2, estrogen receptor, and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues. Appl. Immunohistochem. Mol. Morphol. 19(4), 300\u2013305 (2011).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"9","key":"26715_CR20","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1074\/mcp.M112.023051","volume":"12","author":"M Assadi","year":"2013","unstructured":"Assadi, M. et al. Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays. Mol Cell Proteom. 12(9), 2615\u20132622 (2013).","journal-title":"Mol Cell Proteom."},{"issue":"10","key":"26715_CR21","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1074\/mcp.O114.045542","volume":"14","author":"S Bader","year":"2015","unstructured":"Bader, S. et al. Evaluation of protein profiles from treated xenograft tumor models identifies an antibody panel for formalin-fixed and paraffin-embedded (FFPE) tissue analysis by reverse phase protein arrays (RPPA). Mol. Cell Proteom. 14(10), 2775\u20132785 (2015).","journal-title":"Mol. Cell Proteom."},{"issue":"4","key":"26715_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.molonc.2008.09.003","volume":"2","author":"P Gromov","year":"2008","unstructured":"Gromov, P. et al. A single lysis solution for the analysis of tissue samples by different proteomic technologies. Mol. Oncol. 2(4), 368\u2013379 (2008).","journal-title":"Mol. Oncol."},{"issue":"2","key":"26715_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/microarrays4020098","volume":"4","author":"S Boellner","year":"2015","unstructured":"Boellner, S. & Becker, K. F. Reverse phase protein arrays-quantitative assessment of multiple biomarkers in biopsies for clinical use. Microarrays (Basel). 4(2), 98\u2013114 (2015).","journal-title":"Microarrays (Basel)."},{"issue":"6B","key":"26715_CR24","doi-asserted-by":"publisher","first-page":"E37","DOI":"10.1111\/j.1365-2559.2012.04184.x","volume":"60","author":"C Schuster","year":"2012","unstructured":"Schuster, C. et al. Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues. Histopathology 60(6B), E37-50 (2012).","journal-title":"Histopathology"},{"issue":"1","key":"26715_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1477-5956-10-56","volume":"10","author":"H Guo","year":"2012","unstructured":"Guo, H. et al. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci. 10(1), 56 (2012).","journal-title":"Proteome Sci."},{"issue":"4","key":"26715_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"CE Wu","year":"2018","unstructured":"Wu, C. E. et al. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br. J. Cancer 118(4), 495\u2013508 (2018).","journal-title":"Br. J. Cancer"},{"issue":"23","key":"26715_CR27","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1111\/j.1742-4658.2009.07395.x","volume":"276","author":"H Voshol","year":"2009","unstructured":"Voshol, H., Ehrat, M., Traenkle, J., Bertrand, E. & van Oostrum, J. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J. 276(23), 6871\u20136879 (2009).","journal-title":"FEBS J."},{"issue":"4","key":"26715_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/1615-9861(200204)2:4<383::AID-PROT383>3.0.CO;2-E","volume":"2","author":"M Pawlak","year":"2002","unstructured":"Pawlak, M. et al. Zeptosens\u2019 protein microarrays: A novel high performance microarray platform for low abundance protein analysis. Proteomics 2(4), 383\u2013393 (2002).","journal-title":"Proteomics"},{"issue":"5","key":"26715_CR29","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/pmic.200500078","volume":"6","author":"U Weissenstein","year":"2006","unstructured":"Weissenstein, U. et al. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics 6(5), 1427\u20131436 (2006).","journal-title":"Proteomics"},{"issue":"1","key":"26715_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/19420862.2015.1100787","volume":"8","author":"G Roncador","year":"2016","unstructured":"Roncador, G. et al. The European antibody network\u2019s practical guide to finding and validating suitable antibodies for research. MAbs 8(1), 27\u201336 (2016).","journal-title":"MAbs"},{"issue":"1","key":"26715_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201900091","volume":"14","author":"M Suzuki","year":"2020","unstructured":"Suzuki, M. et al. Utility of a reverse phase protein array to evaluate multiple biomarkers in diffuse large B-cell lymphoma. Proteom. Clin. Appl. 14(1), e1900091 (2020).","journal-title":"Proteom. Clin. Appl."},{"issue":"3","key":"26715_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/modpathol.2011.173","volume":"25","author":"JA Bishop","year":"2012","unstructured":"Bishop, J. A. et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod. Pathol. 25(3), 405\u2013415 (2012).","journal-title":"Mod. Pathol."},{"issue":"9","key":"26715_CR33","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/1759-7714.12819","volume":"9","author":"C Lv","year":"2018","unstructured":"Lv, C. et al. Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. Thorac. Cancer 9(9), 1166\u20131173 (2018).","journal-title":"Thorac. Cancer"},{"issue":"2","key":"26715_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3892\/ol.2013.1734","volume":"7","author":"S Powell","year":"2014","unstructured":"Powell, S., Kaizer, A., Koopmeiners, J. S., Iwamoto, C. & Klein, M. High expression of class III beta-tubulin in small cell lung carcinoma. Oncol. Lett. 7(2), 405\u2013410 (2014).","journal-title":"Oncol. Lett."},{"issue":"3","key":"26715_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","volume":"51","author":"AM Schultheis","year":"2015","unstructured":"Schultheis, A. M. et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur. J. Cancer. 51(3), 421\u2013426 (2015).","journal-title":"Eur. J. Cancer."},{"issue":"1","key":"26715_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s12032-013-0775-5","volume":"31","author":"P Chen","year":"2014","unstructured":"Chen, P. et al. Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis. Med. Oncol. 31(1), 775 (2014).","journal-title":"Med. Oncol."},{"issue":"1","key":"26715_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.lungcan.2004.03.006","volume":"46","author":"S Tanno","year":"2004","unstructured":"Tanno, S., Ohsaki, Y., Nakanishi, K., Toyoshima, E. & Kikuchi, K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46(1), 11\u201319 (2004).","journal-title":"Lung Cancer"},{"issue":"16","key":"26715_CR38","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2217\/fon-2016-0050","volume":"12","author":"A Uguen","year":"2016","unstructured":"Uguen, A. & De Braekeleer, M. ROS1 fusions in cancer: A review. Future Oncol. 12(16), 1911\u20131928 (2016).","journal-title":"Future Oncol."},{"key":"26715_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-020-0127-9","volume":"4","author":"JJ Lin","year":"2020","unstructured":"Lin, J. J. et al. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis. Oncol. 4, 21 (2020).","journal-title":"NPJ Precis. Oncol."},{"issue":"7","key":"26715_CR40","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jtho.2016.03.019","volume":"11","author":"P Viola","year":"2016","unstructured":"Viola, P. et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J. Thorac. Oncol. 11(7), 1029\u20131039 (2016).","journal-title":"J. Thorac. Oncol."},{"issue":"13","key":"26715_CR41","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1002\/pmic.200800159","volume":"9","author":"F Pirnia","year":"2009","unstructured":"Pirnia, F. et al. Novel functional profiling approach combining reverse phase protein microarrays and human 3-D ex vivo tissue cultures: Expression of apoptosis-related proteins in human colon cancer. Proteomics 9(13), 3535\u20133548 (2009).","journal-title":"Proteomics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26715-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26715-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T12:06:04Z","timestamp":1672056364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26715-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["26715"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26715-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"2 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fynn Biotechnologies holds commercial interests on AGLyse protein extraction buffer (the commercial name of related RPPA extraction methods provided in Supplementary tables) and has an associated patent (ZL 2017 1 1323182.6) and offers RPPA screening as a commercial service Dr Achim Treumann has acted in the past as a consultant for Fynn Biotechnologies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22373"}}